Response to Letter to the Editor: Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Synapse
March 3, 2026
Response to Letter to the Editor: Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Key Points
Efficacy of immune checkpoint inhibitors increases with fully vaccinated status against COVID-19.
Patients with recurrent or metastatic head and neck squamous cell carcinoma benefit from enhanced treatment response with said vaccination.
Commentary discusses observations rather than presenting original findings or data insights.
Supports the idea that COVID-19 vaccination may play a role in cancer treatment outcomes.
Abstract
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.